Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)

NCT02151149 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT02151149
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02151149 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+)
Lead sponsor
Celgene
Phase
Phase 4
Overall status
Completed
Start date
June 9, 2014
Completion date
July 14, 2017
Enrollment
143 (actual)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, carcinoma, carcinoma, large cell, lung neoplasm, non-small cell lung cancer, squamous cell carcinoma